Look @ Keytruda's problems ---- Merck, just walk away & come to multiple market expansions & 100% market leverage due to Sequencing, via LL.
It is going to dwarf your reduced ICI market share of current ICI market. Did not know Merck had this serious problem--- but reads as outstanding LL leverage. Again, if....they still want to pursue ICI
I'd pull a move out of the GSK's CEO playbook & just shift the entire corp direction & supporting an LL build-out of a multiple avenues partnership --- even paying big upfront $$$ for Exclusive Rights.
Keytruda Ql3x (subcutaneous Keytruda) faces a significant patent infringement lawsuit from Halozyme Therapeutics, filed in April 2025, which alleges Merck used, without license, its patented technology to create the fast-acting injection.
This legal challenge aims to disrupt the launch of a product vital to Merck's strategy to extend Keytruda's market dominance beyond 2028.
PR Newswire
+2
Key Aspects of the Keytruda Ql3x (SC) Legal Challenge
The Lawsuit:
Halozyme Therapeutics filed a lawsuit in the US District Court for the District of New Jersey alleging that Merck’s subcutaneous (SC) version of Keytruda (marketed as Ql3x) infringes on 15 of its patents, specifically regarding its proprietary hyaluronidase (Mdase) technology.
Technology Dispute:
The dispute centers on the technology that enables the drug to be injected under the skin in a 1-to-2-minute procedure, compared to a 30-minute infusion for the traditional version.
Merck's Defense:
Merck has publicly maintained that the lawsuit has no merit, asserting its confidence in its own intellectual property for the new formulation.
German Injunction:
Halozyme has reportedly secured a preliminary injunction against Merck’s Keytruda SC in Germany, a significant development in their legal battle.
Strategic Importance:
The subcutaneous version is key for Merck to maintain revenue when traditional Keytruda patents begin to expire in 2028.
PR Newswire
+4
______
& subcutaneous for them is only projected $8b Orly
Even if it was the full $28b....LL potential dwarfs it & their entire pipeline
Just offer Cytodtn a 1 n done package deal.....
( hopefully causing a bidding war -- hee hee )
It is going to dwarf your reduced ICI market share of current ICI market. Did not know Merck had this serious problem--- but reads as outstanding LL leverage. Again, if....they still want to pursue ICI
I'd pull a move out of the GSK's CEO playbook & just shift the entire corp direction & supporting an LL build-out of a multiple avenues partnership --- even paying big upfront $$$ for Exclusive Rights.
Keytruda Ql3x (subcutaneous Keytruda) faces a significant patent infringement lawsuit from Halozyme Therapeutics, filed in April 2025, which alleges Merck used, without license, its patented technology to create the fast-acting injection.
This legal challenge aims to disrupt the launch of a product vital to Merck's strategy to extend Keytruda's market dominance beyond 2028.
PR Newswire
+2
Key Aspects of the Keytruda Ql3x (SC) Legal Challenge
The Lawsuit:
Halozyme Therapeutics filed a lawsuit in the US District Court for the District of New Jersey alleging that Merck’s subcutaneous (SC) version of Keytruda (marketed as Ql3x) infringes on 15 of its patents, specifically regarding its proprietary hyaluronidase (Mdase) technology.
Technology Dispute:
The dispute centers on the technology that enables the drug to be injected under the skin in a 1-to-2-minute procedure, compared to a 30-minute infusion for the traditional version.
Merck's Defense:
Merck has publicly maintained that the lawsuit has no merit, asserting its confidence in its own intellectual property for the new formulation.
German Injunction:
Halozyme has reportedly secured a preliminary injunction against Merck’s Keytruda SC in Germany, a significant development in their legal battle.
Strategic Importance:
The subcutaneous version is key for Merck to maintain revenue when traditional Keytruda patents begin to expire in 2028.
PR Newswire
+4
______
& subcutaneous for them is only projected $8b Orly
Even if it was the full $28b....LL potential dwarfs it & their entire pipeline
Just offer Cytodtn a 1 n done package deal.....
( hopefully causing a bidding war -- hee hee )
4
